Oral Leukoplakia Clinical Trial
Official title:
Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study
Verified date | June 2014 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The goal of this clinical research study is to learn how Actos (pioglitazone) may affect oral premalignant lesions (OPLs) and/or the risk of mouth cancer. The safety of this drug will also be studied.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - STAGE I: - Males or females with a suspected or histologically confirmed oral premalignant lesion(s) (up to three target lesions may be followed for the purpose of the study) that has a length (longest diameter) of 8 mm or greater and width (diameter perpendicular to greatest length) of 3 mm or greater in size - If a participant has had a biopsy of the target OPL lesion(s) within 6 weeks prior to the screening visit and archival tissue is available and the participant agrees to have archival tissue used for histologic confirmation and biomarker analysis, then NO additional biopsies (of the OPL) need to be performed at the screening visit; the pre-screening biopsy must undergo centralized pathology review before the second stage of registration can be performed; if archival tissue is not available, a waiting period of 6 weeks from the time of the last biopsy must be observed before re-biopsy for study purposes - If a participant has not had a biopsy of the suspected OPL at the time of the screening visit, then a biopsy of the lesion must be performed during the screening visit; the screening biopsy must undergo centralized pathology review before the second stage of registration can be performed - The participant's life expectancy is > 6 months - The participant has discontinued any other oral cancer chemopreventive therapy at least 12 weeks prior to the baseline visit and all toxicities have been fully resolved; daily aspirin is permitted - The participant is willing and able to fully participate for the duration of the study - Women must not be pregnant or lactating; women of child-bearing potential (women are considered not of childbearing potential if they are at least two years postmenopausal and/or surgically sterile) must have used adequate contraception (abstinence; barrier methods such as IUD, diaphragm with spermicidal gel, condom, or others; and hormonal methods such as birth control pills or others) since her last menses prior to study entry; women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately - Ability to understand and the willingness to sign a written informed consent document - STAGE II: - The participant has one or more target lesions histologically confirmed by a biopsy obtained no more than 9 weeks prior to randomization, that is either: - An EARLY premalignant lesion defined to be at high risk: - Mild dysplasia of any site - Hyperplastic leukoplakia of a high-risk site - Dorsal, lateral or ventral tongue - Floor of mouth - An ADVANCED premalignant lesion defined as the presence of at least one of the following: - Moderate dysplasia - Severe dysplasia (excluding carcinoma in situ) - Erythroplakia (due to the high risk for progression associated with erythroplakia, erythroplakia of any histology will be defined as an ADVANCED oral premalignant lesion) - Hemoglobin levels equal to or above the lower limit of normal - White blood cells >= 3,000/uL - Platelets >= 125,000/uL - Total bilirubin =< 1.5 x ULN - BUN and serum creatinine =< 1.5 x ULN - Glucose, serum < 200 mg/dL - The participant's ECOG performance status is 0 or 1 - If the participant is female and of childbearing potential and not lactating she has a documented negative serum pregnancy test within 14 days prior to randomization - The participant has a baseline EKG that does not show signs of acute cardiac ischemia or cardiac dysrhythmia (except for 1st degree AV block or chronic atrial fibrillation); EKG can be an earlier report within 12 weeks prior to registration - Participants using the drugs listed below may not be randomized unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 3 days prior to starting pioglitazone or placebo on this study; the use of the following drugs or drug classes is prohibited during pioglitazone/placebo treatment: participants taking inhibitors of CYP2C8 (gemfibrozil, ketoconazole, quercetin, trimethoprim), enzyme inducers of CYP2C8 (cortisol, dexamethasone, phenobarbital, rifampin), and CYP3A4 substrate Exclusion Criteria: - The participant has active cancer or carcinoma in situ of the head and neck - The participant has a contraindication to biopsy - The participant has presence of congestive heart failure (New York Heart Association (NYHA) class II-IV), uncontrolled hypertension (systolic > 150 or diastolic > 100), or unstable angina - The participant has any history of congestive heart failure or history of myocardial infarction within the past 6 months - The participant exhibits clinical evidence of active liver disease or history of chronic liver disease - The participant has > CTCAE grade 1 edema - The participant has known diabetes and is on insulin or oral agents; the participant is receiving medical therapy for dysregulated blood sugar - The participant who currently receives an enzyme inhibitor of CYP2C8 (gemfibrozil, ketoconazole, quercetin, trimethoprim), or enzyme inducer of CYP2C8 (cortisol, dexamethasone, phenobarbital, rifampin), or CYP3A4 substrate will not be eligible for randomization after assessing eligibility in stage two unless he/she will not be eligible for randomization after assessing eligibility in stage two unless he/she is willing to stop these drugs and possibly replace them with alternative therapies - The participant currently receives pregabalin or thioridazine - The participant has experienced jaundice with Rezulin (troglitazone) - The participant has a history of colorectal cancer, familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC) - The participant has a history of bladder cancer or in situ bladder cancer - The participant has a history of invasive cancer within the past 18 months (excluding non-melanoma skin cancer and in situ cervical cancer); participants (excluding those with a history of colorectal cancer, FAP, HNPCC, bladder cancer or in situ bladder cancer) who received curative treatment and have shown no evidence of recurrence for 18 months will be eligible |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | European Institute of Oncology | Milano | |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | University of Wisconsin Hospital and Clinics | Madison | Wisconsin |
United States | Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota |
United States | University of Minnesota Medical Center-Fairview | Minneapolis | Minnesota |
United States | Columbia University Medical Center | New York | New York |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | Weill Medical College of Cornell University | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical and histologic response defined as 50% or greater reduction in the sum of the measured products of perpendicular dimensions of the target lesion(s) or improvement in the degree of dysplasia or hyperplasia | Response will be summarized as proportion with a 90% confidence interval, by treatment arm. The primary comparison between the two groups will be based on Cochran-Mantel-Haenszel test with the stage of oral premalignant lesion and the group as stratification factors for testing the difference in the response. | Up to 26 weeks | No |
Secondary | Tissue levels of PPAR gamma, cyclin D1 and p21 as indirect measures of pharmacological effect, TUNEL for apoptosis and Ki-67 for proliferation, transglutaminase and involucrin as markers of squamous differentiation, 15-PGDH and loss of heterozygosity | Will be summarized with mean and standard deviation, median and range if continuous or with frequency if discrete, dichotomous or ordinal, by treatment stratified by stage and group. Generalized linear models will be used for tissue levels of biomarkers in an exploratory analysis with link functions suitable for the nature/type of measurements for these biomarkers. | Baseline | No |
Secondary | Tissue levels of PPAR gamma, cyclin D1 and p21 as indirect measures of pharmacological effect, TUNEL for apoptosis and Ki-67 for proliferation, transglutaminase and involucrin as markers of squamous differentiation, 15-PGDH and loss of heterozygosity | Will be summarized with mean and standard deviation, median and range if continuous or with frequency if discrete, dichotomous or ordinal, by treatment stratified by stage and group. Generalized linear models will be used for tissue levels of biomarkers in an exploratory analysis with link functions suitable for the nature/type of measurements for these biomarkers. | 24 weeks | No |
Secondary | Level of C-reactive protein in plasma | The longitudinal regression models for analysis of the change in CRP in plasma will be used, with suitable transformation if necessary to satisfy the model assumptions, with treatment, stage and biomarker value at screening visit as covariates. | Baseline | No |
Secondary | Level of C-reactive protein in plasma | The longitudinal regression models for analysis of the change in CRP in plasma will be used, with suitable transformation if necessary to satisfy the model assumptions, with treatment, stage and biomarker value at screening visit as covariates. | 24 weeks | No |
Secondary | Tobacco and alcohol use | Tobacco and alcohol use will be summarized by treatment stratified by stage and by group. In addition, the effects of tobacco and alcohol use on the primary endpoint of clinical and pathological response will be assessed using statistical regression models in an exploratory fashion. | Up to 26 weeks | No |
Secondary | Adverse events and clinical laboratory toxicity assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) | Adverse events and clinical laboratory toxicity will be summarized based on the NCI CTCAE v4.0 by treatment. | Up to 26 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05505539 -
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
|
Phase 1 | |
Terminated |
NCT00176566 -
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT04712929 -
Candida Associated Cytokines in Oral Leukoplakia
|
||
Completed |
NCT03031899 -
Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
|
||
Terminated |
NCT00571558 -
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
|
Phase 1 | |
Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
Not yet recruiting |
NCT04732741 -
Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
|
||
Completed |
NCT00369174 -
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
|
Phase 2 | |
Completed |
NCT00099021 -
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Not yet recruiting |
NCT05727761 -
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
|
Phase 2 | |
Active, not recruiting |
NCT02581137 -
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
|
Phase 2 | |
Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
Completed |
NCT00330382 -
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
|
Phase 2 | |
Recruiting |
NCT05237960 -
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
|
Phase 2 | |
Not yet recruiting |
NCT06256809 -
Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
|
||
Recruiting |
NCT04251845 -
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
|
N/A | |
Terminated |
NCT04079491 -
Intra and Extra Oral Inspection of Oral Mucosa
|
||
Recruiting |
NCT00767442 -
Least Invasive Nonlinear Light Microscopy
|
N/A |